Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

09-02-2017 | Image

Table 2: Prognostic and predictive value of TILs in TNBC.

*In continuous evaluation, unit increases in the marker (sTILs or iTILs) — without any cut-off points — are evaluated. In categorical evaluation, the marker is evaluated by applying cut-off points to define high and low groups; cut-off points can vary across different studies. ‡The cut-off for lymphocyte-predominant breast cancer (LPBC) definition was ≥50% or >50% according to different studies. CT, chemotherapy; DFS, disease-free survival; ER, oestrogen receptor; iTIL, intratumoural TIL; OS, overall survival; pCR, pathological complete response; PgR, progesterone receptor; sTIL, stromal TIL; TIL, tumour-inflitrating lymphocyte; TNBC, triple-negative breast cancer.

print
PRINT
Image Credits